Trials / Active Not Recruiting
Active Not RecruitingNCT05751187
Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC Patients
Pembrolizumab Plus Bevacizumab and Chemotherapy as First-Line Treatment for Advanced or Metastatic Non-Squamous NSCLC Patients With EGFR Exon 20 Insertion Mutation: An Open-Label, Single-Arm, Phase II Trial
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 54 (estimated)
- Sponsor
- Shanghai Chest Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to evaluate the efficacy and safety of Pembrolizumab in combination with Bevacizumab and chemotherapy in advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Pembrolizumab | Pembrolizumab was given as 200 milligrams (mg) via intravenous (IV) infusion over 30 minutes on Day 1 of each 21-day cycle. |
| BIOLOGICAL | Bevacizumab | Bevacizumab was given as 15 mg/kg via intravenous (IV) infusion on Day 1 of each 21-day cycle. |
| DRUG | Pemetrexed | Pemetrexed was given as 500 mg/m\^2 via intravenous (IV) infusion (with vitamin supplementation) on Day 1 of each 21-day cycle for 4-6 cycles. |
| DRUG | Cisplatin | Cisplatin was given as 75 mg/m\^2 via intravenous (IV) infusion (administered approximately 30 minutes after pemetrexed infusion) on Day 1 of each 21-day cycle for 4-6 cycles. |
| DRUG | Carboplatin | Carboplatin was given as Aare Under the Curve (AUC) 5 (5 mg/mL/min; over 15-60 min) via intravenous (IV) infusion (administered immediately after pemetrexed infusion) on Day 1 of each 21-day cycle for 4-6 cycles. |
| DIETARY_SUPPLEMENT | Folic acid 350-1000 μg | Orally; at least 5 doses of folic acid must be taken during the 7 days preceding the first dose of pemetrexed, and folic acid dosing must continue during the full course of therapy and for 21 days after the last dose of pemetrexed. |
| DIETARY_SUPPLEMENT | Vitamin B12 1000 μg | Intramuscular injection in the week preceding the first dose of pemetrexed and once every 3 cycles thereafter. Subsequent vitamin B12 injections may be given on the same day as pemetrexed administration. |
| DRUG | Dexamethasone 4 mg | For prophylaxis; orally twice per day (or equivalent). Taken the day before, the day of, and the day after pemetrexed administration. |
Timeline
- Start date
- 2023-06-27
- Primary completion
- 2025-12-15
- Completion
- 2027-12-30
- First posted
- 2023-03-02
- Last updated
- 2026-03-11
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05751187. Inclusion in this directory is not an endorsement.